Yuri E Nikiforov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3467575/publications.pdf

Version: 2024-02-01

204	35,946	5876 81	3312 184
papers	citations	h-index	g-index

206	206	206	18151
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26, 1-133.	2.4	10,674
2	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	3.4	1,192
3	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research, 2003, 63, 1454-7.	0.4	1,132
4	BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5399-5404.	1.8	950
5	Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology, 2011, 7, 569-580.	4.3	798
6	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2012, 22, 1104-1139.	2.4	717
7	Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3390-3397.	1.8	712
8	Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2092-2098.	1.8	674
9	RASPoint Mutations and PAX8-PPARÎ³ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2318-2326.	1.8	664
10	MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1600-1608.	1.8	552
11	Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach. American Journal of Surgical Pathology, 2007, 31, 1256-1264.	2.1	521
12	Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas. American Journal of Surgical Pathology, 2006, 30, 216-222.	2.1	467
13	Proximity of Chromosomal Loci That Participate in Radiation-Induced Rearrangements in Human Cells. Science, 2000, 290, 138-141.	6.0	450
14	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 nextâ€generation sequencing assay. Cancer, 2014, 120, 3627-3634.	2.0	445
15	Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1852-E1860.	1.8	412
16	RET/PTC Rearrangement in Thyroid Tumors. Endocrine Pathology, 2002, 13, 03-16.	5.2	411
17	Targeted Expression of BRAFV600E in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo Dedifferentiation. Cancer Research, 2005, 65, 4238-4245.	0.4	376
18	Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Journal of Clinical Investigation, 2005, 115, 94-101.	3.9	371

#	Article	IF	Citations
19	Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2003, 120, 71-77.	0.4	370
20	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene, 2005, 24, 6646-6656.	2.6	354
21	PAX8-PPARÎ³ Rearrangement in Thyroid Tumors. American Journal of Surgical Pathology, 2002, 26, 1016-1023.	2.1	346
22	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid, 2015, 25, 1217-1223.	2.4	344
23	Thyroid carcinoma: molecular pathways and therapeutic targets. Modern Pathology, 2008, 21, S37-S43.	2.9	331
24	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. JAMA Oncology, 2019, 5, 204.	3.4	317
25	The Increase in Thyroid Cancer Incidence During the Last Four Decades Is Accompanied by a High Frequency ofBRAFMutations and a Sharp Increase inRASMutations. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E276-E285.	1.8	311
26	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2021, 31, 337-386.	2.4	297
27	Molecular Diagnostics and Predictors in Thyroid Cancer. Thyroid, 2009, 19, 1351-1361.	2.4	296
28	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer, 2018, 124, 1682-1690.	2.0	274
29	Pediatric thyroid cancer after the chernobyl disaster. Pathomorphologic study of 84 cases (1991â€“1992) from the republic of Belarus. Cancer, 1994, 74, 748-766.	2.0	259
30	Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Review of Molecular Diagnostics, 2008, 8, 83-95.	1.5	259
31	Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5175-5180.	1.8	252
32	ETV6â€NTRK3 is a common chromosomal rearrangement in radiationâ€associated thyroid cancer. Cancer, 2014, 120, 799-807.	2.0	231
33	Identification of the transformingSTRN-ALKfusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4233-4238.	3.3	230
34	Contribution of molecular testing to thyroid fineâ€needle aspiration cytology of â€œfollicular lesion of undetermined significance/atypia of undetermined significanceâ€. Cancer Cytopathology, 2010, 118, 17-23.	1.4	229
35	MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 2011, 18, 2035-2041.	0.7	216
36	Genetic Alterations Involved in the Transition from Well-Differentiated to Poorly Differentiated and Anaplastic Thyroid Carcinomas. Endocrine Pathology, 2004, 15, 319-328.	5.2	204

#	Article	IF	Citations
37	Molecular Diagnostics of Thyroid Tumors. Archives of Pathology and Laboratory Medicine, 2011, 135, 569-577.	1.2	204
38	Prevalence ofRET/PTCRearrangements in Thyroid Papillary Carcinomas: Effects of the Detection Methods and Genetic Heterogeneity. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3603-3610.	1.8	202
39	NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer, 2016, 122, 1097-1107.	2.0	195
40	Integrated Genomic Analysis of HÃ¼rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell, 2018, 34, 256-270.e5.	7.7	195
41	Cytological features of â€œnoninvasive follicular thyroid neoplasm with papillary-like nuclear featuresâ€•and their correlation with tumor histology. Human Pathology, 2016, 54, 134-142.	1.1	190
42	Solid Variant of Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2001, 25, 1478-1484.	2.1	186
43	Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. American Journal of Clinical Pathology, 2003, 120, 71-7.	0.4	186
44	RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4735-4741.	1.8	181
45	Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2004, 209, 1-6.	3.2	152
46	Role of Molecular Markers in Thyroid Nodule Management: Then and Now. Endocrine Practice, 2017, 23, 979-989.	1.1	151
47	Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features. JAMA Oncology, 2018, 4, 1125.	3.4	151
48	Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery, 2009, 146, 1215-1223.	1.0	149
49	Molecular analysis of thyroid tumors. Modern Pathology, 2011, 24, S34-S43.	2.9	142
50	A combined molecularâ€•pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 2012, 118, 2069-2077.	2.0	139
51	Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathologica, 2010, 119, 641-649.	3.9	136
52	Cytomorphological and molecular genetic findings in pediatric thyroid fineâ€•needle aspiration. Cancer Cytopathology, 2012, 120, 342-350.	1.4	135
53	Cost Impact of Molecular Testing for Indeterminate Thyroid Nodule Fine-Needle Aspiration Biopsies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1905-1912.	1.8	131
54	Increasing incidence of thyroid cancer: controversies explored. Nature Reviews Endocrinology, 2013, 9, 178-184.	4.3	128

#	Article	IF	Citations
55	RASMutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E914-E922.	1.8	128
56	Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas. International Journal of Surgical Pathology, 2002, 10, 15-22.	0.4	126
57	Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation. Clinical Cancer Research, 2006, 12, 1983-1993.	3.2	125
58	Radiation-induced thyroid cancer: What we have learned from Chernobyl. Endocrine Pathology, 2006, 17, 307-318.	5.2	122
59	BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer. Annals of Surgical Oncology, 2013, 20, 47-52.	0.7	121
60	Comprehensive MicroRNA Expression Profiling Identifies Novel Markers in Follicular Variant of Papillary Thyroid Carcinoma. Thyroid, 2013, 23, 1383-1389.	2.4	117
61	Dose-Dependent Generation of RET/PTC in Human Thyroid Cells after in Vitro Exposure to Î³-Radiation: A Model of Carcinogenic Chromosomal Rearrangement Induced by Ionizing Radiation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2364-2369.	1.8	115
62	MicroRNA Expression Profiles in Thyroid Tumors. Endocrine Pathology, 2009, 20, 85-91.	5.2	110
63	Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas andÂBile Duct. Gastroenterology, 2020, 158, 573-582.e2.	0.6	110
64	Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. Modern Pathology, 2018, 31, 39-55.	2.9	107
65	Thyroid Nodules (â‰¥4Âcm): Can Ultrasound and Cytology Reliably Exclude Cancer?. World Journal of Surgery, 2014, 38, 614-621.	0.8	105
66	Noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathology, 2016, 124, 616-620.	1.4	105
67	Thyroid Transcription Factor-1, Thyroglobulin, Cytokeratin 7, and Cytokeratin 20 in Thyroid Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2000, 8, 189-194.	0.6	103
68	Alterations of the <I>BRAF</I> Gene in Thyroid Tumors. Endocrine Pathology, 2005, 16, 163-172.	5.2	101
69	Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro-Oncology, 2016, 18, 379-387.	0.6	101
70	Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer. Annals of Surgery, 2015, 262, 519-525.	2.1	100
71	MicroRNA Expression Array Identifies Novel Diagnostic Markers for Conventional and Oncocytic Follicular Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1-E7.	1.8	99
72	RET/PTC and PAX8/PPARÎ³ chromosomal rearrangements in postâ€Chernobyl thyroid cancer and their association with iodineâ€131 radiation dose and other characteristics. Cancer, 2013, 119, 1792-1799.	2.0	99

#	Article	IF	Citations
73	Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Modern Pathology, 2020, 33, 1264-1274.	2.9	96
74	Proliferative Activity of Human Thyroid Cells in Various Age Groups and Its Correlation with the Risk of Thyroid Cancer after Radiation Exposure. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2672-2677.	1.8	93
75	Molecular Analysis of Thyroid Tumors. Endocrine Pathology, 2011, 22, 126-133.	5.2	93
76	The Histopathology of BRAF-V600Eâ€“mutated Lung Adenocarcinoma. American Journal of Surgical Pathology, 2008, 32, 1317-1321.	2.1	90
77	Pulmonary Langerhans Cell Histiocytosis. Chest, 2013, 143, 1679-1684.	0.4	88
78	Follicular cell-derived thyroid cancer. Nature Reviews Disease Primers, 2015, 1, 15077.	18.1	88
79	Molecular profile of hyalinizing trabecular tumours of the thyroid: High prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. European Journal of Cancer, 2005, 41, 816-821.	1.3	87
80	MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. Journal of Molecular Endocrinology, 2014, 52, 181-189.	1.1	86
81	New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers. Clinical Cancer Research, 2013, 19, 2283-2288.	3.2	84
82	PAX8/PPARÎ³Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma. Thyroid, 2014, 24, 1369-1374.	2.4	83
83	Histopathologic and Clinical Characterization of Thyroid Tumors Carrying theBRAF^{K601E}Mutation. Thyroid, 2016, 26, 242-247.	2.4	83
84	Downregulation of Rap1GAP through Epigenetic Silencing and Loss of Heterozygosity Promotes Invasion and Progression of Thyroid Tumors. Cancer Research, 2010, 70, 1389-1397.	0.4	82
85	Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. Endocrine-Related Cancer, 2016, 23, 295-301.	1.6	81
86	A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma. Endocrine Pathology, 2009, 20, 122-126.	5.2	74
87	Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies. Journal of Molecular Diagnostics, 2010, 12, 487-492.	1.2	72
88	BRAF mutation detection in indeterminate thyroid cytology specimens. Cancer Cytopathology, 2013, 121, 197-205.	1.4	71
89	HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocrine-Related Cancer, 2007, 14, 445-452.	1.6	70
90	GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid, 2019, 29, 161-173.	2.4	69

#	Article	IF	Citations
91	A Clinical Algorithm for Fine-Needle Aspiration Molecular Testing Effectively Guides the Appropriate Extent of Initial Thyroidectomy. Annals of Surgery, 2014, 260, 163-168.	2.1	66
92	A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2016, 18, 165-175.	1.2	66
93	Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathology, 2014, 122, 873-882.	1.4	63
94	Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay. Pediatric and Developmental Pathology, 2016, 19, 115-122.	0.5	63
95	Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure. American Journal of Surgical Pathology, 2017, 41, 446-457.	2.1	61
96	Molecular approaches to thyroid cancer diagnosis. Endocrine-Related Cancer, 2014, 21, T301-13.	1.6	60
97	Both BRAF V600E Mutation and Older Age (â‰¥65ÂYears) are Associated with Recurrent Papillary Thyroid Cancer. Annals of Surgical Oncology, 2011, 18, 3566-3571.	0.7	59
98	THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2307-2312.	3.3	58
99	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	1.4	58
100	Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology. Cancer Cytopathology, 2019, 127, 225-230.	1.4	58
101	RET/PTC Rearrangementâ€"A Link between Hashimotoâ€™s Thyroiditis and Thyroid Cancerâ€¦or Not. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2040-2042.	1.8	57
102	Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Medicine, 2019, 8, 5831-5839.	1.3	57
103	Can Malignant Thyroid Nodules Be Distinguished from Benign Thyroid Nodules in Children and Adolescents by Clinical Characteristics? A Review of 89 Pediatric Patients with Thyroid Nodules. Thyroid, 2015, 25, 392-400.	2.4	56
104	Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery, 2017, 161, 168-175.	1.0	56
105	Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer. Journal of the National Cancer Institute, 2018, 110, 371-378.	3.0	52
106	Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the chernobyl disaster. Cancer, 1995, 76, 900-909.	2.0	51
107	Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathology, 2019, 127, 161-168.	1.4	50
108	Mechanisms of chromosomal rearrangements in solid tumors: The model of papillary thyroid carcinoma. Molecular and Cellular Endocrinology, 2010, 321, 36-43.	1.6	49

#	Article	IF	Citations
109	Changing the Cancer Diagnosis: The Case of Follicular Variant of Papillary Thyroid Cancerâ€" Primum Non Nocere and NIFTP. Thyroid, 2016, 26, 869-871.	2.4	48
110	Homologous chromosomes make contact at the sites of double-strand breaks in genes in somatic G ₀ /G ₁ -phase human cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9454-9459.	3.3	47
111	Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope, 2013, 123, 1059-1064.	1.1	47
112	Molecular and Histopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1586-1591.	2.1	46
113	An International Interobserver Variability Reporting of the Nuclear Scoring Criteria to Diagnose Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: a Validation Study. Endocrine Pathology, 2018, 29, 242-249.	5.2	46
114	The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Human Pathology, 2018, 74, 1-4.	1.1	45
115	Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules. International Journal of Pediatric Otorhinolaryngology, 2013, 77, 1697-1700.	0.4	43
116	Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia: a clinicopathologic and molecular analysis of a distinct entity. Modern Pathology, 2017, 30, 329-339.	2.9	43
117	Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population. Archives of Pathology and Laboratory Medicine, 2016, 140, 134-139.	1.2	41
118	AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: Stateâ€ofâ€theâ€art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features. Head and Neck, 2018, 40, 1881-1888.	0.9	41
119	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	0.9	41
120	Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): Achieving Better Agreement By Refining Diagnostic Criteria. Clinics, 2018, 73, e576.	0.6	40
121	Is ionizing radiation responsible for the increasing incidence of thyroid cancer?. Cancer, 2010, 116, 1626-1628.	2.0	39
122	MicroRNA Dysregulation in Human Thyroid Cells Following Exposure to Ionizing Radiation. Thyroid, 2011, 21, 261-266.	2.4	39
123	The influence of the noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features (NIFTP) resection diagnosis on the falseâ€positive thyroid cytology rate relates to quality assurance thresholds and the application of NIFTP criteria. Cancer Cytopathology, 2017, 125, 692-700.	1.4	39
124	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	1.4	39
125	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched caseâ€control study. Cancer, 2021, 127, 1779-1787.	2.0	38
126	Characterization of thyroid cancer driven by known and novel ALK fusions. Endocrine-Related Cancer, 2019, 26, 803-814.	1.6	38

#	Article	IF	Citations
127	RAS Mutation-Positive Follicular Variant of Papillary Thyroid Carcinoma Arising in a Struma Ovarii. Endocrine Pathology, 2010, 21, 144-147.	5.2	35
128	Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery, 2013, 154, 730-738.	1.0	34
129	Frequent loss of heterozygosity at chromosome 3p14.2-3p21 in human pancreatic islet cell tumours. Clinical Endocrinology, 1999, 51, 27-33.	1.2	33
130	Prevalence of minisatellite and microsatellite instability in radiation-induced post-Chernobyl pediatric thyroid carcinomas. Oncogene, 1998, 17, 1983-1988.	2.6	32
131	DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. Journal of Clinical Investigation, 2020, 130, 1479-1490.	3.9	31
132	Amiodarone-Induced Thyrotoxicosis and Thyroid Cancer: Clinical, Immunohistochemical, and Molecular Genetic Studies of a Case and Review of the Literature. Archives of Pathology and Laboratory Medicine, 2004, 128, 807-810.	1.2	31
133	Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroidâ€stimulating hormone receptor gene mutations. Diagnostic Cytopathology, 2018, 46, 369-377.	0.5	30
134	Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer Cytopathology, 2021, 129, 33-42.	1.4	30
135	Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort. British Journal of Cancer, 2015, 113, 1556-1564.	2.9	29
136	Gene position within chromosome territories correlates with their involvement in distinct rearrangement types in thyroid cancer cells. Genes Chromosomes and Cancer, 2009, 48, 222-228.	1.5	28
137	Targeted mutation detection in breast cancer using MammaSeqâ„¢. Breast Cancer Research, 2019, 21, 22.	2.2	28
138	Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Managementâ€"A Case Report. Thyroid, 2015, 25, 1375-1378.	2.4	27
139	Ramifications of New Terminology for Encapsulated Follicular Variant of Papillary Thyroid Carcinomaâ€"Reply. JAMA Oncology, 2016, 2, 1098.	3.4	27
140	SeqReporter. Journal of Molecular Diagnostics, 2014, 16, 11-22.	1.2	26
141	Noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features (NIFTP) in thyroid tumor classification. Pathology International, 2018, 68, 327-333.	0.6	26
142	Prevalence and Spectrum of DICER1 Mutations in Adult-onset Thyroid Nodules with Indeterminate Cytology. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e968-e977.	1.8	26
143	Summary statement: Utility of molecular marker testing in thyroid cancer. Surgery, 2010, 148, 1313-1315.	1.0	25
144	Molecular landscape of thyroid cancer continues to be deciphered. Nature Reviews Endocrinology, 2016, 12, 67-68.	4.3	25

#	Article	IF	Citations
145	DNA Topoisomerases Participate in Fragility of the Oncogene RET. PLoS ONE, 2013, 8, e75741.	1.1	24
146	Molecular alterations in HÃ¼rthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	1.6	23
147	Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Modern Pathology, 2012, 25, 1203-1211.	2.9	21
148	GLIS rearrangements in thyroid nodules: A key to preoperative diagnosis of hyalinizing trabecular tumor. Cancer Cytopathology, 2019, 127, 560-566.	1.4	21
149	Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma. Thyroid, 2019, 29, 1425-1437.	2.4	21
150	Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children. JAMA Oncology, 2022, 8, 1323.	3.4	21
151	Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head and Neck, 2013, 35, 1499-1506.	0.9	20
152	â€œColloidâ€Richâ€•follicular neoplasm/suspicious for follicular neoplasm thyroid fineâ€needle aspiration specimens: Cytologic, histologic, and molecular basis for considering an alternate view. Cancer Cytopathology, 2013, 121, 718-728.	1.4	20
153	Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples. Thyroid, 2021, 31, 589-595.	2.4	19
154	Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?. Thyroid, 2021, 31, 1673-1682.	2.4	19
155	Intraoperative Pathologic Examination in the Era of Molecular Testing for Differentiated Thyroid Cancer. Journal of the American College of Surgeons, 2012, 215, 546-554.	0.2	18
156	Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma. Endocrine Pathology, 2016, 27, 70-75.	5.2	18
157	Knockdown ofIG20Gene Expression Renders Thyroid Cancer Cells Susceptible to Apoptosis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1467-1471.	1.8	16
158	Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma. Pediatric and Developmental Pathology, 2015, 18, 318-323.	0.5	16
159	Clinicopathologic Characteristics of Thyroid Nodules Positive for theTHADA-IGF2BP3Fusion on Preoperative Molecular Analysis. Thyroid, 2021, 31, 1212-1218.	2.4	16
160	Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget, 2018, 9, 13612-13622.	0.8	16
161	Formation of carcinogenic chromosomal rearrangements in human thyroid cells after induction of double-strand DNA breaks by restriction endonucleases. Endocrine-Related Cancer, 2012, 19, 271-281.	1.6	14
162	Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery. Head and Neck, 2021, 43, 920-927.	0.9	14

#	Article	IF	Citations
163	Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid. Endocrine Pathology, 2015, 26, 315-319.	5.2	13
164	Synchronous Independent Papillary Thyroid Carcinomas in Struma Ovarii and the Thyroid Gland With Different RAS Mutations. Journal of the Endocrine Society, 2018, 2, 944-948.	0.1	13
165	Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion. American Journal of Pathology, 2018, 188, 2653-2661.	1.9	13
166	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. Scientific Reports, 2020, 10, 8031.	1.6	12
167	MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. Cancers, 2019, 11, 885.	1.7	10
168	Frequency of close positioning of chromosomal loci detected by FRET correlates with their participation in carcinogenic rearrangements in human cells. Genes Chromosomes and Cancer, 2012, 51, 1037-1044.	1.5	9
169	DNA Fragile Site Breakage as a Measure of Chemical Exposure and Predictor of Individual Susceptibility to Form Oncogenic Rearrangements. Carcinogenesis, 2017, 38, bgw210.	1.3	9
170	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Thyroid Carcinoma. Archives of Pathology and Laboratory Medicine, 2017, 141, 559-563.	1.2	9
171	Thyroseq V3 Molecular Profiling for Tailoring the Surgical Management of HÃ¼rthle Cell Neoplasms. Case Reports in Endocrinology, 2018, 2018, 1-4.	0.2	9
172	Clinical Implementation and Validation of Automated Human Genome Variation Society (HGVS) Nomenclature System for Next-Generation Sequencingâ€“Based Assays for Cancer. Journal of Molecular Diagnostics, 2018, 20, 628-634.	1.2	9
173	Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fineâ€needle aspirates diagnosed as follicular neoplasm of HÃ¼rthle cell (oncocytic) type. Cancer Cytopathology, 2021, 129, 788-797.	1.4	9
174	A Case of Papillary Thyroid Carcinoma and Kostmann Syndrome: A Genomic Theranostic Approach for Comprehensive Treatment. American Journal of Case Reports, 2019, 20, 1027-1034.	0.3	9
175	Non-invasive follicular thyroid neoplasm with papillary-like nuclei: reducing overtreatment by reclassifying an indolent variant of papillary thyroid cancer. Journal of Clinical Pathology, 2016, 69, 947-948.	1.0	8
176	The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4577-e4592.	1.8	8
177	Molecular Profile and Clinical Outcomes in Differentiated Thyroid Cancer Patients Presenting with Bone Metastasis. Endocrine Practice, 2019, 25, 1255-1262.	1.1	7
178	Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas. Thyroid, 2019, 29, 1279-1285.	2.4	7
179	On target cell numbers in radiation-induced H4 - RET mediated papillary thyroid cancer. Radiation and Environmental Biophysics, 2001, 40, 191-197.	0.6	6
180	Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?. Endocrine-Related Cancer, 2021, 28, 621-630.	1.6	6

#	Article	IF	Citations
181	Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations. Endocrine-Related Cancer, 2022, 29, 467-473.	1.6	6
182	What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision. Thyroid, 2022, 32, 421-428.	2.4	4
183	Clinical Utility of GlioSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients With Brain Tumors. Journal of Neuropathology and Experimental Neurology, 2019, 78, 694-702.	0.9	3
184	The Molecular Pathways Induced by Radiation and Leading to Thyroid Carcinogenesis. , 2004, 122, 191-206.		2
185	Recent Developments in the Molecular Biology of the Thyroid. , 2010, , 237-260.		2
186	Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features. Cancer Cytopathology, 2017, 125, 292-293.	1.4	2
187	Incidental Diagnosis of Parathyroid Lesions by Preoperative Use of Nextâ€Generation Molecular Testing. World Journal of Surgery, 2018, 42, 2840-2845.	0.8	2
188	OR21-02 Impact of Nodule Size on the Probability of Hurthle Cell Carcinoma and Other Cancers in Thyroid Nodules with Multiple Chromosomal Copy Number Alterations. Journal of the Endocrine Society, 2020, 4, .	0.1	2
189	MON-570 Clinical Utility of ThyroSeq v3 Genomic Classifier Test in Detecting Gene Fusions in Thyroid Nodules. Journal of the Endocrine Society, 2019, 3, .	0.1	2
190	Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing. Endocrine-Related Cancer, 2022, 29, 513-520.	1.6	2
191	Significance of what is not sampled: Characteristics of thyroid nonmicrocarcinomas (>1.0 cm) that were not targeted. Cancer Cytopathology, 2015, 123, 678-683.	1.4	1
192	Utilization of Molecular Markers in the Diagnosis and Management of Thyroid Nodules. , 2018, , 465-487.		1
193	Response to Letter to the Editor regarding followâ€up for NIFTP. Head and Neck, 2019, 41, 835-835.	0.9	1
194	Letter to the Editor: Prevalence of WWP1 Gene Mutations in Patients with Thyroid Nodules. Thyroid, 2021, 31, 1147-1148.	2.4	1
195	Application of Molecular Tests in Indeterminate Thyroid FNA. , 2020, , 227-239.		1
196	BRAF Mutations in Papillary Thyroid Carcinoma. , 2010, 15, 121-125.		0
197	In Reply. Archives of Pathology and Laboratory Medicine, 2015, 139, 967-968.	1.2	0
198	Positive PIK3CA (P.H1047R) Mutation in a Benign Thyroid Nodule of a Patient With Men-1 Syndrome. AACE Clinical Case Reports, 2018, 4, e320-e323.	0.4	0

#	Article	IF	Citations
199	Molecular Genetics and Diagnostics of Thyroid Cancer. , 2019, , 549-561.		0
200	MON-LB79 Do Ultrasound Patterns and Clinical Parameters Modify the Probability of Thyroid Cancer Predicted by Molecular Testing in Thyroid Nodules With Indeterminate Cytology?. Journal of the Endocrine Society, 2020, 4, .	0.1	0
201	Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP). , 2021, , 213-217.e2.		0
202	DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. FASEB Journal, 2010, 24, 874.1.	0.2	0
203	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. VideoEndocrinology, 2016, 3, .	0.1	0
204	Molecular profiling of papillary thyroid carcinomas in healthcare workers exposed to low dose radiation at the workplace. Endocrine, 2022, 76, 95.	1.1	0